Background: Polycythemia vera is a possible cause of recurrent ischemic stroke which can be prevented. Aim: Describe a junctional ischemic stroke without large arterial trunks stenosis associated with an acute coronary syndrome. Case Presentation: A 66-years-old man was admitted for abrupt recurrent right hemiparesis related to bilateral and junctional ischemic stroke lesions. He had a medical history of a vertebrobasilar ischemic stroke concurrent with an acute coronary syndrome with normal coronary arteries. Transthoracic echocardiogram showed small apical akinesia. Hemoglobin level was 18.9 g/dl with a hematocrit of 57.6%. The endogenous erythropoietin was 1.3 mIU/ml with JAK2 V617F mutation positivity (37%). After eight months of treatment (hydroxycarbamide + aspirin + allopurinol) hemoglobin was 12.5 g/dL. Conclusion: This case illustrates the most suggestive features of PV particularly the ischemic stroke junctional topography.
References
[1]
De Stefano, V., Za, T., Rossi, E., Vannucchi, A.M., Ruggeri, M., Elli, E., et al. (2008) Recurrent Thrombosis in Patients with Polycythemia Vera and Essential Thrombocythemia: Incidence, Risk Factors, and Effect of Treatments. Haematologica, 93, 372-380. https://doi.org/10.3324/haematol.12053
[2]
Spivak, J.L. (2018) Polycythemia Vera. Current Treatment Options in Oncology, 19, Article No. 12. https://doi.org/10.1007/s11864-018-0529-x
[3]
Hart, R.G. and Kanter MC. (1990) Hematological Disorders and Ischemic Stroke: A Selective Review. Stroke, 21, 1111-1121. https://doi.org/10.1161/01.STR.21.8.1111
[4]
Lee, G. and Arcasoy, M.O. (2015) The Clinical and Laboratory Evaluation of the Patient with Erythrocytosis. European Journal of Internal Medicine, 26, 297-302. https://doi.org/10.1016/j.ejim.2015.03.007
[5]
Pedersen, O., Larsen, M.L., Kristensen, S.D., Hvas, A.M. and Grove, E.L. (2017) Recurrent Cardiovascular Events Despite Antiplatelet Therapy in a Patient with Polycythemia Vera and Accelerated Platelet Turnover. American Journal of Case Reports, 18, 945-948. https://doi.org/10.12659/AJCR.904148
[6]
Kroll, M.H., Michaelis, L.C. and Verstovsek, S. (2015) Mechanisms of Thrombogenesis in Polycythemia Vera. Blood Reviews, 29, 215-221. https://doi.org/10.1016/j.blre.2014.12.002
[7]
Richter, V., Savery, M.D., Gassmann, M., et al. (2011) Excessive Erythrocytosis Compromises the Blood-Endothelium Interface in Erythropoietin-Overexpressing Mice. The Journal of Physiology, 589, 5181-5192. https://doi.org/10.1113/jphysiol.2011.209262
[8]
Landolfi, R., Marchioli, R., Kutti, J., Gisslinger, H., Tognoni, G., Patrono, C., et al. (2004) Efficacy and Safety of Low-Dose Aspirin in Polycythemia Vera. The New England Journal of Medicine, 350, 114-124. https://doi.org/10.1056/NEJMoa035572
